Birgitte Rønø, PhD, joined Evaxion as Senior Director of Immuno-Oncology in 2017 and was appointed Chief Scientific Officer in September 2021.
Dr. Rønø has more than 15 years of experience in biopharmaceutical drug discovery from academia and industry and received her PhD in experimental oncology and immunology from the National Institutes of Health, Bethesda, USA, and Copenhagen University Hospital, Denmark.
